<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>PHHY2012JP113594</report-id><gender>female</gender><reactions><reaction>Skin eruption</reaction><reaction>Oedema</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>TASIGNA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Chronic myeloid leukaemia</indication></indications><outcomes/><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053107_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133616</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012JP113594</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-03</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-03</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012JP113594</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>JP</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<reaction>
				<primarysourcereaction>Skin eruption</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Skin eruption</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Rash</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201106</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Oedema</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Oedema</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oedema</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201206</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TASIGNA</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Chronic myeloid leukaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-06-04</drugstartdate>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oedema</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012JP113594 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 03 Dec 2012: This report refers to a 46-year old female patient. This patient received <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.87" ID="282225">Tasigna </Semaphore>(<Semaphore x="928154" class="Medicine" value="nilotinib" score="0.49" ID="278855">nilotinib</Semaphore>) for newly <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore><Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">phase <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic <Semaphore x="3120003" class="MedDRA LLT" value="Myeloid leukaemia" score="1.00" ID="10028549">myeloid leukemia </Semaphore></Semaphore></Semaphore></Semaphore>from 04 Jun 2011. In Jun 2011, the same month that <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.87" ID="282225">Tasigna </Semaphore>was started, the patient experienced <Semaphore x="3251213" class="MedDRA LLT" value="Skin oedema" score="1.00" ID="10058679"><Semaphore x="3221160" class="MedDRA LLT" value="Rash" score="1.00" ID="10037844"><Semaphore x="2528100" class="AnatomicStructure" value="Skin" score="1.00" ID="C12470">skin </Semaphore>eruption </Semaphore>and oedema</Semaphore>, which were mild. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>with <Semaphore x="69227" class="Medicine" value="Allegra" score="0.49" ID="253051">Allegra </Semaphore>(<Semaphore x="575418" class="Medicine" value="Fexofenadine hydrochloride" score="0.49" ID="249793">fexofenadine hydrochloride</Semaphore>) and <Semaphore x="1081705" class="Medicine" value="prednisoLONE" score="0.74" ID="291320">prednisolone </Semaphore>at a dose of 5 mg were given for <Semaphore x="3251213" class="MedDRA LLT" value="Skin oedema" score="1.00" ID="10058679"><Semaphore x="3221160" class="MedDRA LLT" value="Rash" score="1.00" ID="10037844"><Semaphore x="2528100" class="AnatomicStructure" value="Skin" score="1.00" ID="C12470">skin </Semaphore>eruption </Semaphore>and oedema</Semaphore>. On 15 Jul 2011, the dose of <Semaphore x="1081705" class="Medicine" value="prednisoLONE" score="0.74" ID="291320">prednisolone </Semaphore>was decreased to 2.5 mg. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of <Semaphore x="3251213" class="MedDRA LLT" value="Skin oedema" score="1.00" ID="10058679"><Semaphore x="3221160" class="MedDRA LLT" value="Rash" score="1.00" ID="10037844"><Semaphore x="2528100" class="AnatomicStructure" value="Skin" score="1.00" ID="C12470">skin </Semaphore>eruption </Semaphore>and oedema </Semaphore>was reported as recovery on an unspecified date. <Semaphore x="3251213" class="MedDRA LLT" value="Skin oedema" score="1.00" ID="10058679"><Semaphore x="3221160" class="MedDRA LLT" value="Rash" score="1.00" ID="10037844"><Semaphore x="2528100" class="AnatomicStructure" value="Skin" score="1.00" ID="C12470">Skin </Semaphore>eruption </Semaphore>and oedema </Semaphore>were considered non serious by the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician</Semaphore>. The <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>reported that <Semaphore x="3251213" class="MedDRA LLT" value="Skin oedema" score="1.00" ID="10058679"><Semaphore x="3221160" class="MedDRA LLT" value="Rash" score="1.00" ID="10037844"><Semaphore x="2528100" class="AnatomicStructure" value="Skin" score="1.00" ID="C12470">skin </Semaphore>eruption </Semaphore>and oedema </Semaphore>were related to <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.87" ID="282225">Tasigna</Semaphore>.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>